Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers

  • Hans Vasen
  • , Isaura Ibrahim
  • , Kristin Robbers
  • , Anneke M. Van Mil
  • , Thomas Potjer
  • , Bert A. Bonsing
  • , Wilma Bergman
  • , Martin Wasser
  • , Hans Morreau
  • , Wouter H. De Vos Tot Nederveen Cappel
  • , Carmen Guillen Ponce
  • , Alfredo Carrato
  • , Julie Earl
  • , Evelina Mocci
  • , Enrique Vazquez-Sequeiros
  • , Alfonso Sanjuanbenito
  • , Maria Muñoz-Beltran
  • , José Montans
  • , Emily P. Slater
  • , Elvira Matthäi
  • Volker Fendrich, Detlef K. Bartsch, Christoph Schicker, Martin Steinkamp, Jens Figiel, Günter Klöppel, Peter Langer, Irene Esposito

Research output: Contribution to journalArticlepeer-review

317 Scopus citations

Abstract

Purpose: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Hereditary factors play a role in the development of PDAC in 3% to 5% of all patients. Surveillance of high-risk groups, may facilitate detection of PDAC at an early stage. The aim of this study was to assess whether surveillance aids detection of early-stage PDAC or precursor lesions (PRLs) and improves the prognosis. Patients and Methods: Screening outcomes were collected from three European centers that conduct prospective screening in high-risk groups including families with clustering of PDAC (familial pancreatic cancer [FPC]) or families with a gene defect that predisposes to PDAC. The surveillance program consisted of annual magnetic resonance imaging, magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound. Results: Four hundred eleven asymptomatic individuals participated in the surveillance programs, including 178 CDKN2A mutation carriers, 214 individuals with FPC, and 19 BRCA1/2 or PALB2 mutation carriers. PDAC was detected in 13 (7.3%) of 178 CDKN2A mutation carriers. The resection rate was 75%, and the 5-year survival rate was 24%. Two CDKN2A mutation carriers (1%) underwent surgical resection for low-risk PRL. Two individuals (0.9%) in the FPC cohort had a pancreatic tumor, including one advanced PDAC and one early grade 2 neuroendocrine tumor. Thirteen individualswith FPC (6.1%) underwent surgical resection for a suspected PRL, but only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial neoplasms). One BRCA2 mutation carrier was found to have PDAC, and another BRCA2 mutation carrier and a PALB2 mutation carrier underwent surgery and were found to have low-risk PRL. No serious complications occurred as consequence of the program. Conclusion: Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident.

Original languageEnglish
Pages (from-to)2010-2019
Number of pages10
JournalJournal of Clinical Oncology
Volume34
Issue number17
DOIs
StatePublished - 10 Jun 2016

Fingerprint

Dive into the research topics of 'Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers'. Together they form a unique fingerprint.

Cite this